Are Six Dealers of Anti-Cancer Drugs Under Investigation?
Synopsis
In a significant move, the Delhi government has uncovered violations by six dealers of anti-cancer drugs during a quality check. Legal action has been initiated against these firms. This drive underscores the government's commitment to safeguarding patient safety and ensuring the availability of quality medications.
Key Takeaways
Six dealers of anti-cancer drugs are under investigation.
Legal action has been initiated against violating firms.
Inspections were conducted in various key areas of Delhi.
The government maintains a zero-tolerance policy towards counterfeit medications.
Patient safety is a top priority for the Delhi government.
New Delhi, Feb 9 (NationPress) A recent initiative by the Delhi government aimed at assessing the quality of anti-cancer medications revealed that six companies were violating the Drugs and Cosmetics Rules, as stated by Health Minister Pankaj Kumar Singh on Monday. He announced that legal proceedings have been initiated against the offenders.
Various teams from the Drugs Control Department carried out inspections at 25 retail and wholesale outlets selling anti-cancer drugs in significant parts of the city, particularly around major hospital clusters and pharmaceutical hubs located in East, South, West, and North-West Delhi.
The inspections, aimed at eliminating counterfeit or substandard medications, spanned areas such as Laxmi Nagar, Yusuf Sarai, Green Park, Okhla Industrial Area, Paschim Vihar, Dwarka, and Rohini.
“Ensuring patient safety is our utmost priority. We are committed to making certain that only safe, effective, and high-quality medicines are accessible to the citizens of Delhi,” the Minister asserted.
To assess the quality and compliance of the medications provided to patients, a total of 33 legal samples and 22 specimen samples of anti-cancer drugs were gathered for comprehensive laboratory testing and analysis, according to an official statement.
Minister Pankaj Kumar Singh emphasized that the Delhi government maintains a zero-tolerance policy toward counterfeit or substandard medications, particularly those utilized in cancer treatment.
He indicated that ongoing inspections, rigorous enforcement, and continuous monitoring will be a focal point to safeguard patients.
The Minister reiterated that anti-cancer drugs are essential, life-saving treatments, and any compromise on quality could pose significant risks to patient safety.
In response, the monitoring of the supply chain has been intensified to guarantee that only safe, effective, and standards-compliant medications reach hospitals, pharmacies, and patients, he stated.
The Minister highlighted that such initiatives will be conducted consistently and that the government will impose strict penalties on any entity found breaching drug safety regulations.
He also urged the public and healthcare institutions to obtain medicines solely from licensed vendors and to report any suspected irregularities to the Drugs Control Department without delay.
Point of View
We believe that the Delhi government's initiative to monitor anti-cancer drug quality is a proactive step towards ensuring patient safety. This move not only emphasizes the importance of stringent drug regulations but also showcases the government's commitment to combatting counterfeit medications in the healthcare sector.
NationPress
20 Jun 2026
Frequently Asked Questions
Why is the Delhi government inspecting anti-cancer drugs?
The inspections aim to ensure the quality and safety of anti-cancer medications, protecting patients from counterfeit or substandard products.
What actions are being taken against the violating firms?
Legal action has been initiated against the six firms found to be contravening the Drugs and Cosmetics Rules.
What areas were inspected for compliance?
Inspections were conducted in key locations including Laxmi Nagar, Yusuf Sarai, Green Park, Okhla Industrial Area, Paschim Vihar, Dwarka, and Rohini.
How does the government ensure patient safety?
The government follows a zero-tolerance policy towards counterfeit drugs and conducts continuous inspections and monitoring of the supply chain.
What should the public do if they suspect irregularities?
The public and healthcare institutions are advised to procure medicines only from licensed sources and report any suspected irregularities to the Drugs Control Department.
